VTRS
Viatris Inc (VTRS) Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Inc (NASDAQ: VTRS) FY 2026 Other Release
Viatris Inc (VTRS) Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Inc (NASDAQ: VTRS) FY 2026 Other Release
Viatris Inc (VTRS) Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris Inc (NASDAQ: VTRS) FY 2026 Other Release
Viatris Inc (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc (NASDAQ: VTRS) Q4 2025 Earnings Call dated Feb. 26, 2026 Corporate Participants: Operator Bill Szablewski — Head of…
Viatris Inc (VTRS) Sec Form 10K
Viatris Inc (NASDAQ: VTRS) Sec Form 10K
Viatris Inc (VTRS) Sec Form 8K
Viatris Inc (NASDAQ: VTRS) Sec Form 8K
Viatris Inc (VTRS) Dividend Update
Viatris Inc (NASDAQ: VTRS) Q1 2026 Dividend Update
Viatris Inc (VTRS) Q4 2025 Earnings Results
Viatris Inc (NASDAQ: VTRS) Q4 2025 Earnings Release
Viatris Inc (VTRS) Q4 2025 Earnings Call
Viatris Inc (NASDAQ: VTRS) Q4 2025 Earnings Conference
Viatris Inc (VTRS) FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Viatris Inc (NASDAQ: VTRS) FY 2026 Other Release